European Archives - Page 993 of 1132 - European Medical Journal

Development and Translation of Therapies for Spinal Muscular Atrophy

Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disorder characterised by widespread loss of lower motor neurons from the spinal…

Wilson’s Disease: An Inherited, Silent, Copper Intoxication Disease

Wilson’s disease is a rare, autosomal recessive, genetic, copper overload disease, which evokes multiple motor or neuropsychiatric symptoms and liver…

Multiple Sclerosis: Where Do We Go From Here?

Multiple sclerosis (MS) is the most common cause of neurological disability in young populations after trauma and represents a significant personal…

Whole Spectrum of Natural Progression of Haemangioblastoma Seen Within a Single Patient: A Very Rare Case Report and Literature Review

This paper reports a rare case of sporadic variation of haemangioblastoma (HB) presenting as multiple lesions within the posterior fossa. A whole…

Advances in the Management of Transient Ischaemic Attack and Stroke

Among many important advances in the management of transient ischaemic attack (TIA) and stroke are: the updated definition of TIA; risk stratification…

EMJ

Laser Ablation: A Low-Risk, Highly Effective Option for Prostate Cancer Patients

NEW, less invasive therapy has been discovered for the treatment of prostate cancer. The therapy provides a middle ground for men who have previously had…

EMJ

Risk Warning for Higher Salt Consumption in CKD Patients

HIGH salt intake could lead to an increased risk of cardiovascular disease (CVD) among chronic kidney disease (CKD) patients, according to a recent study…

EMJ Interventional Cardiology 4 [Suppl 12] 2016

Bioresorbable vascular scaffold (BRS/bioabsorbable stents are a new and promising generation of intravascular devices that may potentially circumvent…

Bioresorbable Vascular Scaffolds as Optimal Treatment for Selected Patients in our Clinical Practice

Bioresorbable vascular scaffolds (BRS)/bioabsorbable stents are a new and promising generation of intravascular devices that may potentially circumvent…

New Data Show Sandoz Biosimilar Etanercept Candidate Has Equivalent Efficacy to Originator Product

Holzkirchen, July 7, 2016 – Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, today announced results from the EGALITY trial…